1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp. Warrant

BCTXZ
BriaCell Therapeutics Corp. WarrantUS flagNASDAQ Global Select
0.09
USD
-0.02
- -
173,493.00Market Cap
BriaCell Therapeutics Corp. Warrant
BCTXZ
(NASDAQ Global Select)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
-1
- -
-8
-3
-2
-3
-4
-5
-4
-14
-27
-20
-5
-19
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
1
4
2
1
- -
1
1
1
1
-1
-4
57
41
25
-4
10
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
1
12
10
9
- -
1
1
1
1
-1
-4
28
10
-4
-3
12
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-3.98
- -
- -
- -
- -
- -
- -
- -
- -
-173.87
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
Total Current Assets
8
7
15
Cash, Cash Equivalents & STI
6
5
12
Accounts Receivable, Net
2
2
2
Inventories
- -
- -
- -
Total Current Liabilities
5
5
4
Payables & Accruals
5
5
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-10,376.01%
-135%
-28.92%
Free Cash Flow
86.23%
119.51%
3.53%
Net Income, GAAP
24.5%
44.44%
-76.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
SteadyMed Ltd. (STDY)
Belite Bio, Inc (BLTE)
Infinity Pharmaceuticals, Inc. (INFI)
PaxMedica, Inc. Common Stock (PXMD)
Genfit S.A. (GNFT.PA)
VBI Vaccines Inc. (VBIV)
Business
A clinical-stage biotechnology firm, BriaCell Therapeutics Corp. focuses its efforts on pioneering innovative immunotherapies for the treatment of various cancers. The company's leading therapeutic candidate, Bria-IMT™, is an off-the-shelf, targeted cell-based immunotherapy currently undergoing a pivotal Phase 3 combination study for patients with metastatic breast cancer, where it has received U.S. FDA Fast Track designation. Beyond Bria-IMT™, BriaCell is advancing Bria-OTS™ and its optimized version, Bria-OTS+™, a sophisticated platform for personalized off-the-shelf immunotherapies. This platform leverages HLA-matching with premanufactured cells to treat advanced breast cancer, prostate cancer, and other solid tumors, with Bria-OTS currently in Phase 1/2 clinical studies. Additionally, through its subsidiary BriaPro Therapeutics, the company has strategically expanded into small molecule discovery, collaborating with Receptor.AI to develop AI-driven kinase inhibitors for oncology. BriaCell maintains significant alliances, including an ongoing collaboration with the National Cancer Institute for preclinical studies and a recent partnership with Memorial Sloan Kettering Cancer Center's Accelerator program to expedite the development of its Bria-OTS+ platform. Headquartered in West Vancouver, Canada, BriaCell Therapeutics Corp. is dedicated to transforming cancer care for patients facing limited treatment options.